Axogen to Participate in 24th Annual Morgan Stanley Global Healthcare Conference

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, will participate in the 24th Annual Morgan Stanley Global Healthcare Conference. The company's management will be available for one-on-one investor meetings on Tuesday, September 15, 2026.

Axogen, operating under the stock symbol AXGN, is dedicated to advancing the science and commercialization of technologies for peripheral nerve regeneration and repair. The firm's mission is to restore nerve function and enhance the quality of life for patients suffering from peripheral nerve injuries. Axogen's team is committed to providing innovative, clinically proven, and cost-effective solutions for surgeons and healthcare providers.

Peripheral nerves play a crucial role in the body by transmitting motor and sensory signals. Traumatic injuries or surgical procedures can disrupt these pathways, leading to the loss of muscle or organ function, sensory impairment, or the onset of pain. Axogen offers a comprehensive portfolio of products designed to address these challenges, including Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.

At the conference, Axogen's management will discuss the company's latest advancements and future plans, providing investors with insights into the company's growth and strategic initiatives. The event is expected to attract a diverse group of healthcare professionals and investors interested in the latest developments in nerve regeneration and repair technologies.